59 results about "Tumor cytotoxicity" patented technology

The invention belongs to the field of medical biology engineering, and particularly relates to a method for effectively multiplying gamma delta T cells by stimulating peripheral blood in vitro and application of the method. The method comprises the step of using feeder cells, an OKT3 (ornithine ketoacid transaminase) antibody, interleukin-2 and zoledronic acid. The feeder cells are formed by specifically inserting CD64, CD86 and CD137L genes in a target site of a genome of the feeder cells. After the zoledronic acid and the nterleukin-2 are used for increasing the proportion of the gamma delta T cells of the peripheral blood, protein products of genes, the OKT3 antibody and the interleukin-2 act in a combined manner, and the gamma delta T cells can be stimulated so that a large amount of gamma delta T cells can be multiplied. The multiplied gamma delta T cells can be used for killing tumor cells which are pretreated by the zoledronic acid, or the tumor cells can be directly killed by modifying and expressing chimeric antigen receptors (CAR) via a genetic engineering means. The gamma delta T cells which are obtained by the method have complete anti-tumor cytotoxicity, and can kill solid tumor cells and non-solid tumor cells.

A method for improving the cytotoxic effect of Ecteinascidin-743 (ET-743) or an analog thereof on a tumor cell population in a patient the method including administering to the patient, sequentially or simultaneously, a therapeutically effective combination of a composition including ET-743 and an amount of a composition including a PARP-1 inhibitor effective to increase the cytotoxic effect of ET-743 on the tumor cell population. Anti-tumor compositions containing a therapeutically effective amount of ET-743 and an amount of a PARP-1 inhibitor effective to increase the tumor cytotoxicity of the ET-743 are also presented.

The invention discloses a preparation method of an effective part of dendrobium officinale. The method comprises steps as follows: firstly, extracting fat-soluble extracts represented by bibenzyl from the dendrobium officinale with a high-concentration alcohol-water system, refining the extracts with a macroporous resin method to obtain a total bibenzyl effective part with the bibenzyl content higher than 50%, and preparing dregs of the extracts into dendrobium officinale total polysaccharides with water extraction and alcohol precipitation methods; drying and evenly mixing the total bibenzyl effective part and the dendrobium officinale total polysaccharides obtained in two steps to obtain a dendrobium officinale total effective part extract. According to the method, the defect of the extremely low extraction rate of dendrobium officinale fat-soluble active ingredients represented by the bibenzyl with traditional methods such as a water decoction method, a tea making method and the like is overcome, the utilization efficiency of the effective part of the dendrobium officinale is improved substantially, pharmacological anti-oxidation animal experiments and anti-tumor cytotoxicity experiments prove that the activity of the effective part is significantly higher than that of traditional aqueous extracts, and the effective part has the characteristics of high extraction rate and high activity.

The invention discloses a sulfur-substituted podophyllum derivative and a bioconversion, separation and purification method thereof. The sulfur-substituted podophyllum derivative with antitumor activity, shown as Formula (I) or (II), is obtained by modifying the molecular structure of podophyllotoxin or 4'-demethylepipodophyllotoxin through a bioconversion method. Preliminary study on in-vitro tumor cytotoxicity shows that the sulfur-substituted podophyllum derivative disclosed by the invention has stronger inhabitation action on the growth of tumor cells such as BGC823, HepG2, A549 and the like, and thus can be used as an antitumor compound to achieve a potential drug development value. According to the invention, the podophyllotoxin and the 4'-demethylepipodophyllotoxin are converted into the sulfur-substituted podophyllum derivative by using a bioconversion method, and therefore, the sulfur-substituted podophyllum derivative has the advantages of low cost and E-factor, simplicity in operation, easiness for culturing, controllable quality, capability of effectively preventing chemical residuals and the like.

Provided are a method of ex-vivo culture of natural killer (NK) cells by treating the cells with a reactive oxygen species (ROS) inhibitor and/or a p53 protein inhibitor; and a composition comprising the cultured NK cells. By reducing the activity of ROS and p53 proteins during ex-vivo culture, NK cells may have achieved greater expansion efficiency without altering their anti-tumor cytotoxicity.

The invention relates to a plasmid structure for expressing CD19CAR and knocking down T cell surface PD-1 expression simultaneously. The plasmid structure comprises an H1 promoter, an anti-PD-1shRNA sequence started by the H1 promoter, an EF1alpha promoter and a three-generation CD19CAR sequence started by the EF1alpha promoter that are connected in series in order. The three-generation CD19CAR sequence consists of a CD19 single chain variable region, a human CD8alpha hinge region, a human CD28 transmembrane region and an intracellular region, a human 41BB intracellular region and a human CD3zeta intracellular region that are connected in series. The plasmid structure provided by the invention is transduced into T cells by a lentivirus, and the CART cell production process is significantlysimplified than using CRISPR/Cas9 for knockout of PD-1. Moreover, the CART cells show enhanced tumor cytotoxicity killing ability and increased persistent cell repair and cytokine secretion ability after antigenic stimulation in vitro.

The invention discloses a pair of eudesmane sesquiterpene lactone epimers (1S,4S,5S,6S,7S,8S,9R,10S)-1,9-diacetoxy-4-hydroxy-6-isobutyryloxyprostatolide and (1S,4S,5R,6S,7S,8S,9R,10S)-1,9-diacetoxy-4-hydroxyl-6-isobutyryloxyprostatolide, pharmaceutically acceptable salts or solvates of the epimers, and pharmacodynamic activity of a pharmaceutical composition composed of the compounds, and mainly relates to a medical application of an anti-breast cancer medicine in inducing breast cancer cell MCF-7 cell morphology to retract and become round and the level of intracellular reactive oxygen species (ROS) to rise to show tumor cytotoxicity.

The invention discloses a c-Myc gene expression inhibitor, and application thereof to preparing anti-tumor medicines. The c-Myc gene expression inhibitor is a pyrrole-imidazole polyamide small molecule. The pyrrole-imidazole polyamide small molecule is targeted to a c-Myc gene promoter sequence through a recognizing and pairing mode, and the expression of a c-Myc gene is silenced. Polyamide PA6 presents good tumor cytotoxicity, the growth of tumor cells can be restrained, and the apoptosis of the tumor cells is induced.

The invention belongs to the field of biotechnology and microbial animal cell lines and particularly relates to a method for cultivating lymph-node autologous CIK (cytokine-induced killer) cells and application of the lymph-node autologous CIK cells. The CIK cells are obtained by in-vitro cultivation of isolated lymph node tissue obtained in surgery in patients with lung cancer and are compared with the CIK cells obtained from cultivation of isolated peripheral blood, biological characteristics of the CIK cells and cytotoxicity effect on pulmonary granule cancer cells are observed, the result shows that the isolated lymph node issue of the surgical patients can be completely used for cultivation of CIK, in-vitro tumor-cytotoxicity cells are powerful in activity, and the activity and cancer inhibition function are prior to the CIK cells of the peripheral blood. The CIK cells can be used for preparing pulmonary granule and cancer inhibition products and made into compounds with chemotherapy drugs as well as used for adoptive immunity and intervention for postoperative patients with lung cancers, and occurrence rate for recurrence and metastasis of the postoperative patients with the lung cancers is beneficially decreased.

The invention discloses an orthoester 5-fluorouracil prodrug molecule. The orthoester 5-fluorouracil prodrug molecule is N-5-fluorouracil1-ethyl-2-carbonalkoxy-(1,3) dioxolane-4-methylformamide havinga structure as shown in formula (I) described in the specification, wherein n=2-32 and m=n+2. The invention further discloses a preparation method of the abovementioned prodrug molecule and a nanoparticle prepared therefrom and an application thereof. The orthoester 5-fluorouracil prodrug molecule, the preparation method and the nanoparticle and the application thereof have the advantages that the nanoparticle prepared by the orthoester 5-fluorouracil prodrug molecule not only has the advantages of a small molecule prodrug but also is endowed with the advantage of a nano drug delivery system(that is a drug carrier), the prodrug nanoparticle not only has excellent acid degradation property and reduced tumor cytotoxicity and realizes passive targeting enrichment of a drug in a tumor, the nanoparticle has high drug loading capacity because the drug is used as a main part of the carrier, and the nanoparticle is capable of loading other antitumor drugs and achieves the effect of cooperatively treating the tumor and thus has good application prospects in the field of tumor treatment.

The invention discloses an antitumor drug based on a PGA-RB (Polyglutamic Acid-Rose Bengal) bound compound and a preparation method and application of the antitumor drug. The structural formula of the antitumor drug is shown as Formula I, wherein the bonding rate of RB is 5-30 percent. According to the invention, RB is modified to obtain an RB derivative, the RB derivative is bound with PGA to obtain the antitumor drug, the antitumor drug can be self-assembled in a water solution into nanometer particles of 100-200 nm, and the nanometer particles have the advantages of high stability, good biocompatibility, long in-vivo circulation time, obviously enhanced toxicity to cancer cells under light, and the like; and the preparation method has simple steps and is convenient to operate.

The invention relates to a 1-(3', 4', 5'-trisubstituted phenyl)-isoquinolin compound with tumor cytotoxicity shown in a formula (1) and intermediate compounds thereof or pharmaceutical salts or solvates thereof, The invention also relates to a method for preparing the compounds in the formula (1), pharmaceutical compositions and medicinal application thereof. The compounds have certain activity of inhibiting growth of tumor cells, and can be expected to be used as anti-tumor drugs. A structural formula (1) of the invention is shown in a figure.

The invention provides a preparation method and application of a metal organic framework drug-loaded nano system based on a small molecule drug, MIT and HYD are jointly loaded in pores of a metal organic framework ZIF-8 through a simple and rapid method to prepare nano particles, and active targeting HA modification of tumor cells is realized. The problems of poor stability of MIT and HYD and co-delivery of MIT and HYD are solved, and the immune efficacy of chemotherapeutic drugs is enhanced. The (M+H) (at) ZIF/HA intravenous injection preparation is low in toxicity, good in safety, high in tumor cell toxicity and obvious in solid tumor inhibition effect.

The invention discloses a biologically active peptide and a method for proliferating a CIK cell in vitro. The method comprises the following steps: drawing peripheral venous blood, separating a single karyocyte, culturing the single karyocyte in a culture flask pre-coated with the biologically active peptide and an anti-CD3 monoclonal antibody by virtue of a serum-free culture medium, only adding IL-2 and the serum-free culture medium in a culture system afterwards, and performing culturing for 14 to 21 days under the conditions of 37 DEG C and 5% CO2, wherein the biologically active peptide is obtained by performing enzymatic hydrolysis on a raw material cicada with trypsin, entrapping a component of a molecular weight of 3,000 to 1,000u by virtue of an ultrafiltration membrane and performing freeze-drying. The biologically active peptide can be used for efficiently inducing in-vitro proliferation of the CIK cell, high survival rate and high purity are achieved, and the CIK cell obtained by the method for proliferating the CIK cell in vitro has good in-vitro tumor cytotoxicity effects and in-vivo tumor suppression effects; in addition, the biologically active peptide which is low in cost and readily available is used according to the method instead of recombinant human IFN-gamma and IL-1alpha in a conventional culturing method, so that the cost is low.

The present invention provides a means of selectively killing epithelial cell carcinomas by administering a CXCR4-specific sequence of the Gp120 protein or Nef proteins or the proteins themselves (the modulators) such as that found in strains HIV-1, HIV-2, SIV, or FIV CXCR4-specific Gp 120 sequences or Nef proteins or sequences may be delivered to the mucosa or systemically. The mucosal means of application include oral, intranasal, ocular, intravaginal, rectal, and/or intraurethral administration in liquid or particulate form.

The invention discloses hyaluronic acid artesunate, a nano-micelle preparation of hyaluronic acid artesunate, and a preparation method and use of the nano-micelle preparation. The active ingredient hyaluronic acid artesunate consists of artesunate and hyaluronic acid, wherein artesunate serves as a main active ingredient, hyaluronic acid serves as a carrier and a targeting molecule and is connected with artesunate through a chemical bond to form hyaluronic acid artesunate, and then self-assembly is performed to form a nano-micelle and freeze-drying is performed to obtain the nano-micelle preparation. A particle size of the hyaluronic acid artesunate nano-micelle is 100-200 nm, the freeze-dried preparation is good in stability, and has a relatively good acidity responsive release characteristic after being injected into a body, and cytotoxicity tests prove that compared with the artesunate pure medicine, the nano-micelle preparation has stronger tumor cytotoxicity effects. The nano-micelle preparation has the characteristics of strong targeting property, long circulation and low toxicity.

The invention relates to a substituted cinnamic acid derivatives comprising amides substituent with a structure shown as Formula (I) and cytotoxic activity as well as medicine salts or solvates of the derivatives. The invention also relates to the preparation method and medicine purpose of the compounds with a Formula (I) The compounds of invention are provided with the activity of inhibiting growth of human oral squamous carcinoma cells, namely KB cell. The derivatives can be expected to be used as an antitumor drug.